Metastatic pheochromocytoma and paraganglioma: focus on therapeutics - PubMed (original) (raw)
Review
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics
P-F Plouin et al. Horm Metab Res. 2012 May.
Abstract
Metastatic pheochromocytomas and paragangliomas are rare and challenging tumors. The tumor burden, combined with excessive catecholamine production, predispose to a broad spectrum of complications that range from spinal cord compression to any organ damage, all of which may lead to decreased quality of life and overall survival. Current therapies include surgery, systemic chemotherapy and radiopharmaceutical agents. Surgery is often a preferred therapy because it may cure or allow a long-term remission in patients with locoregional or isolated resectable distant metastases. Additionally, surgery can palliate symptoms related to tumor burden or catecholamine excess. However, in patients for whom surgery is not an option, systemic chemotherapy and radiopharmaceutical agents are preferred options. Systemic chemotherapy and radiopharmaceutical agents such as 131I-Metaiodobenzylguanidine (131I-MIBG) may cause partial responses or stabilization of disease with better blood pressure control and symptomatic and performance status improvement. However, as these therapies are only palliative, patients' quality of life and personal preferences should always be considered. The recognition of molecular pathways involved in the pheochromocytoma and paraganglioma tumorigenesis has driven the development of new therapeutic options. Agents such as tyrosine kinase, MAPK, PI3K, or hypoxia inducible factor inhibitors, alone or in combination, may represent novel therapeutic strategies that could be evaluated in prospective clinical trials. Transcriptional profiling and the development of personalized cancer medicine will help to pave the way for more specific therapeutic approaches and combinations.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
- Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice.
Varghese J, Skefos CM, Jimenez C. Varghese J, et al. Mol Cell Endocrinol. 2024 Oct 1;592:112344. doi: 10.1016/j.mce.2024.112344. Epub 2024 Aug 31. Mol Cell Endocrinol. 2024. PMID: 39182716 Review. - The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. Chrisoulidou A, et al. Endocr Relat Cancer. 2007 Sep;14(3):569-85. doi: 10.1677/ERC-07-0074. Endocr Relat Cancer. 2007. PMID: 17914089 Review. - Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L, Habra MA, Jiménez C. Santarpia L, et al. Horm Metab Res. 2009 Sep;41(9):680-6. doi: 10.1055/s-0029-1214381. Epub 2009 Apr 2. Horm Metab Res. 2009. PMID: 19343618 Review. - High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. Rose B, et al. Cancer. 2003 Jul 15;98(2):239-48. doi: 10.1002/cncr.11518. Cancer. 2003. PMID: 12872341 - Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ, Hendel HW. Andersen KF, et al. Cancer Treat Rev. 2011 Apr;37(2):111-9. doi: 10.1016/j.ctrv.2010.07.002. Epub 2010 Aug 2. Cancer Treat Rev. 2011. PMID: 20675056 Review.
Cited by
- CT-based radiomics research for discriminating the risk stratification of pheochromocytoma using different machine learning models: a multi-center study.
Zhao J, Zhan Y, Zhou Y, Yang Z, Xiong X, Ye Y, Yao B, Xu S, Peng Y, Xiao X, Zeng X, Zuo M, Dai X, Gong L. Zhao J, et al. Abdom Radiol (NY). 2024 May;49(5):1569-1583. doi: 10.1007/s00261-024-04279-8. Epub 2024 Apr 8. Abdom Radiol (NY). 2024. PMID: 38587628 - [18F]FDOPA PET/CT is superior to [68Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytoma.
Iversen P, Kramer S, Ebbehoj A, Søndergaard E, Stochholm K, Poulsen PL, Hjorthaug K. Iversen P, et al. EJNMMI Res. 2023 Dec 18;13(1):108. doi: 10.1186/s13550-023-01056-4. EJNMMI Res. 2023. PMID: 38110755 Free PMC article. - Expression of endocan and vascular endothelial growth factor and their correlation with histopathological prognostic parameters in pheochromocytoma.
Kocabaş M, Can M, Karaköse M, Esen HH, Kulaksizoğlu M, Karakurt F. Kocabaş M, et al. Endocrine. 2023 Dec;82(3):638-645. doi: 10.1007/s12020-023-03489-2. Epub 2023 Aug 18. Endocrine. 2023. PMID: 37596456 - Multimodality Imaging Appearance of Intrapericardial Paragangliomas.
Palacio D, Gutierrez MDP, Kuyumcu G, Rounseville B, Shponka V, Betancourt S. Palacio D, et al. Indian J Radiol Imaging. 2023 Jan 31;33(3):394-399. doi: 10.1055/s-0041-1741092. eCollection 2023 Jul. Indian J Radiol Imaging. 2023. PMID: 37362356 Free PMC article. - Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, Stambler N, DiPippo VA, Pryma DA. Jimenez C, et al. Endocr Relat Cancer. 2023 Jan 5;30(2):e220236. doi: 10.1530/ERC-22-0236. Print 2023 Feb 1. Endocr Relat Cancer. 2023. PMID: 36472300 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical